메뉴 건너뛰기




Volumn 18, Issue 6, 2014, Pages 753-759

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions

Author keywords

Dipeptidyl peptidase 4 inhibitors; glucagon like peptide 1; glucagon like peptide 1 agonist; glucose dependent intestinal polypeptide; incretin; type 2 diabetes

Indexed keywords


EID: 84995559883     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.141319     Document Type: Review
Times cited : (69)

References (46)
  • 1
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.
    • (2007) Gastroenterology , vol.132 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 2
    • 67651173077 scopus 로고    scopus 로고
    • Incretin-based therapies for type 2 diabetes mellitus
    • Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-9.
    • (2009) Nat Rev Endocrinol , vol.5 , pp. 262-269
    • Lovshin, J.A.1    Drucker, D.J.2
  • 3
    • 0036188070 scopus 로고    scopus 로고
    • Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
    • Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002;172:355-62.
    • (2002) J Endocrinol , vol.172 , pp. 355-362
    • Deacon, C.F.1    Wamberg, S.2    Bie, P.3    Hughes, T.E.4    Holst, J.J.5
  • 5
    • 0038359686 scopus 로고    scopus 로고
    • Effects of GLP-1-(7-36) NH2, GLP-1-(7-37), and GLP-1-(9-36) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans
    • Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36) NH2, GLP-1-(7-37), and GLP-1-(9-36) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003;88:1772-9.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 1772-1779
    • Vahl, T.P.1    Paty, B.W.2    Fuller, B.D.3    Prigeon, R.L.4    D'Alessio, D.A.5
  • 6
    • 77954866977 scopus 로고    scopus 로고
    • The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
    • Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, et al. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2010;73:189-96.
    • (2010) Clin Endocrinol (Oxf) , vol.73 , pp. 189-196
    • Bock, G.1    Dalla Man, C.2    Micheletto, F.3    Basu, R.4    Giesler, P.D.5    Laugen, J.6
  • 7
    • 0029111540 scopus 로고
    • Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides
    • Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995;58:149-56.
    • (1995) Regul Pept , vol.58 , pp. 149-156
    • Hupe-Sodmann, K.1    McGregor, G.P.2    Bridenbaugh, R.3    Göke, R.4    Göke, B.5    Thole, H.6
  • 8
    • 0030758090 scopus 로고    scopus 로고
    • Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells
    • Hupe-Sodmann K, Göke R, Göke B, Thole HH, Zimmermann B, Voigt K, et al. Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides 1997;18:625-32.
    • (1997) Peptides , vol.18 , pp. 625-632
    • Hupe-Sodmann, K.1    Göke, R.2    Göke, B.3    Thole, H.H.4    Zimmermann, B.5    Voigt, K.6
  • 9
    • 55549136417 scopus 로고    scopus 로고
    • Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study
    • DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52.
    • (2008) Curr Med Res Opin , vol.24 , pp. 2943-2952
    • DeFronzo, R.A.1    Okerson, T.2    Viswanathan, P.3    Guan, X.4    Holcombe, J.H.5    MacConell, L.6
  • 10
    • 77955262909 scopus 로고    scopus 로고
    • Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study
    • Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study. Diabetes Care 2010;33:1509-15.
    • (2010) Diabetes Care , vol.33 , pp. 1509-1515
    • Arnolds, S.1    Dellweg, S.2    Clair, J.3    Dain, M.P.4    Nauck, M.A.5    Rave, K.6
  • 11
    • 80053390364 scopus 로고    scopus 로고
    • Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: A randomized, double-blind, crossover study
    • Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: A randomized, double-blind, crossover study. Diabetes Obes Metab 2011;13:982-9.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 982-989
    • Berg, J.K.1    Shenouda, S.K.2    Heilmann, C.R.3    Gray, A.L.4    Holcombe, J.H.5
  • 12
    • 84995693403 scopus 로고    scopus 로고
    • [Last accessed on 2014 Jun 20]
    • Available from: http://www.en.sanofi.com/img/content/study/EFC10780-summary.pdf. [Last accessed on 2014 Jun 20].
  • 13
    • 77952309372 scopus 로고    scopus 로고
    • Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial
    • Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56.
    • (2010) Lancet , vol.375 , pp. 1447-1456
    • Pratley, R.E.1    Nauck, M.2    Bailey, T.3    Montanya, E.4    Cuddihy, R.5    Filetti, S.6
  • 14
    • 84878837962 scopus 로고    scopus 로고
    • Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: A randomised clinical trial
    • Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, et al. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: A randomised clinical trial. Diabetologia 2013;56:1503-11.
    • (2013) Diabetologia , vol.56 , pp. 1503-1511
    • Charbonnel, B.1    Steinberg, H.2    Eymard, E.3    Xu, L.4    Thakkar, P.5    Prabhu, V.6
  • 15
    • 77955573674 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
    • Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet 2010;376:431-9.
    • (2010) Lancet , vol.376 , pp. 431-439
    • Bergenstal, R.M.1    Wysham, C.2    Macconell, L.3    Malloy, J.4    Walsh, B.5    Yan, P.6
  • 16
    • 84859013614 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study
    • Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study. Diabetes Care 2012;35:252-8.
    • (2012) Diabetes Care , vol.35 , pp. 252-258
    • Russell-Jones, D.1    Cuddihy, R.M.2    Hanefeld, M.3    Kumar, A.4    González, J.G.5    Chan, M.6
  • 17
    • 84904992244 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)
    • Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-58.
    • (2014) Diabetes Care , vol.37 , pp. 2149-2158
    • Nauck, M.1    Weinstock, R.S.2    Umpierrez, G.E.3    Guerci, B.4    Skrivanek, Z.5    Milicevic, Z.6
  • 18
    • 84904963065 scopus 로고    scopus 로고
    • HARMONY 3: 104-week randomized, double-blind, placebo-and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin
    • Ahrén B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, et al. HARMONY 3: 104-week randomized, double-blind, placebo-and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37:2141-8.
    • (2014) Diabetes Care , vol.37 , pp. 2141-2148
    • Ahrén, B.1    Johnson, S.L.2    Stewart, M.3    Cirkel, D.T.4    Yang, F.5    Perry, C.6
  • 19
    • 84863309250 scopus 로고    scopus 로고
    • Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes - A review and meta analysis
    • Deacon CF, Mannucci E, Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012;14:762-7.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 762-767
    • Deacon, C.F.1    Mannucci, E.2    Ahrén, B.3
  • 20
  • 21
    • 84881560141 scopus 로고    scopus 로고
    • Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
    • Nauck MA, Baranov O, Ritzel RA, Meier JJ. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 2013;56:1878-83.
    • (2013) Diabetologia , vol.56 , pp. 1878-1883
    • Nauck, M.A.1    Baranov, O.2    Ritzel, R.A.3    Meier, J.J.4
  • 23
    • 20244385394 scopus 로고    scopus 로고
    • Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors
    • Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004;53:1326-35.
    • (2004) Diabetes , vol.53 , pp. 1326-1335
    • Hansotia, T.1    Baggio, L.L.2    Delmeire, D.3    Hinke, S.A.4    Yamada, Y.5    Tsukiyama, K.6
  • 24
    • 34249902025 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action
    • Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43.
    • (2007) Diabetes Care , vol.30 , pp. 1335-1343
    • Drucker, D.J.1
  • 25
    • 17844407465 scopus 로고    scopus 로고
    • The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
    • Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 2005;48:608-11.
    • (2005) Diabetologia , vol.48 , pp. 608-611
    • Nauck, M.A.1    El-Ouaghlidi, A.2
  • 26
    • 84903177441 scopus 로고    scopus 로고
    • Direct enhancement of insulin secretion by dipeptidyl peptidase 4 inhibitors in pancreatic islets: Studies in incretin receptor deficient mice
    • Abstract 44, EASD Barcelona
    • Omar B, Ohlsson L, Yamada Y, Seino Y, Ahren B. Direct enhancement of insulin secretion by dipeptidyl peptidase 4 inhibitors in pancreatic islets: Studies in incretin receptor deficient mice. Diabetologia. 2013;Abstract 44, EASD Barcelona.
    • (2013) Diabetologia
    • Omar, B.1    Ohlsson, L.2    Yamada, Y.3    Seino, Y.4    Ahren, B.5
  • 27
    • 0037928769 scopus 로고    scopus 로고
    • The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: In vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38)
    • Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: In vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 2003;278:22418-23.
    • (2003) J Biol Chem , vol.278 , pp. 22418-22423
    • Zhu, L.1    Tamvakopoulos, C.2    Xie, D.3    Dragovic, J.4    Shen, X.5    Fenyk-Melody, J.E.6
  • 28
    • 15444372531 scopus 로고    scopus 로고
    • Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice
    • Ahrén B, Hughes TE. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 2005;146:2055-9.
    • (2005) Endocrinology , vol.146 , pp. 2055-2059
    • Ahrén, B.1    Hughes, T.E.2
  • 29
    • 84995739241 scopus 로고    scopus 로고
    • Oxyntomodulin has significant acute glucoregulatory effects comparable to liraglutide in subjects with type 2 diabetes
    • Abstract 48, EASD Barcelona
    • Shankar SS, Shankar R, Mixson L, Pramanik B, Stoch S, Steinberg HO, et al. Oxyntomodulin has significant acute glucoregulatory effects comparable to liraglutide in subjects with type 2 diabetes. Diabetolgia 2014;Abstract 48, EASD Barcelona.
    • (2014) Diabetolgia
    • Shankar, S.S.1    Shankar, R.2    Mixson, L.3    Pramanik, B.4    Stoch, S.5    Steinberg, H.O.6
  • 30
    • 33749044201 scopus 로고    scopus 로고
    • GLP-1 secretion is decreased in NIDDM patients compared to matched control subjects with normal glucose tolerance
    • Toft-Nielsen M, Damholt M, Hilsted J, Hughes TE, Krarup T, Madsbad S, et al. GLP-1 secretion is decreased in NIDDM patients compared to matched control subjects with normal glucose tolerance. Diabetologia 1999;A40:143.
    • (1999) Diabetologia , vol.A40 , pp. 143
    • Toft-Nielsen, M.1    Damholt, M.2    Hilsted, J.3    Hughes, T.E.4    Krarup, T.5    Madsbad, S.6
  • 31
    • 0034090145 scopus 로고    scopus 로고
    • Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose
    • Meneilly GS, Demuth HU, McIntosh CH, Pederson RA. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 2000;17:346-50.
    • (2000) Diabet Med , vol.17 , pp. 346-350
    • Meneilly, G.S.1    Demuth, H.U.2    McIntosh, C.H.3    Pederson, R.A.4
  • 33
    • 21344451403 scopus 로고    scopus 로고
    • Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
    • Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48:1168-72.
    • (2005) Diabetologia , vol.48 , pp. 1168-1172
    • Mannucci, E.1    Pala, L.2    Ciani, S.3    Bardini, G.4    Pezzatini, A.5    Sposato, I.6
  • 34
    • 33749064594 scopus 로고    scopus 로고
    • Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
    • Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006;155:485-93.
    • (2006) Eur J Endocrinol , vol.155 , pp. 485-493
    • Ryskjaer, J.1    Deacon, C.F.2    Carr, R.D.3    Krarup, T.4    Madsbad, S.5    Holst, J.6
  • 35
    • 37549030476 scopus 로고    scopus 로고
    • Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1 (7-36) amide degradation in type 2 diabetic subjects
    • McKillop AM, Duffy NA, Lindsay JR, O'Harte FP, Bell PM, Flatt PR. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1 (7-36) amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008;79:79-85.
    • (2008) Diabetes Res Clin Pract , vol.79 , pp. 79-85
    • McKillop, A.M.1    Duffy, N.A.2    Lindsay, J.R.3    O'Harte, F.P.4    Bell, P.M.5    Flatt, P.R.6
  • 36
  • 37
    • 77957881269 scopus 로고    scopus 로고
    • Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: A novel liver disease biomarker
    • Firneisz G, Varga T, Lengyel G, Fehér J, Ghyczy D, Wichmann B, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: A novel liver disease biomarker. PLoS One 2010;5:e12226.
    • (2010) PLoS One , vol.5 , pp. e12226
    • Firneisz, G.1    Varga, T.2    Lengyel, G.3    Fehér, J.4    Ghyczy, D.5    Wichmann, B.6
  • 38
    • 77952704834 scopus 로고    scopus 로고
    • Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions
    • Pala L, Ciani S, Dicembrini I, Bardini G, Cresci B, Pezzatini A, et al. Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. Diabet Med 2010;27:691-5.
    • (2010) Diabet Med , vol.27 , pp. 691-695
    • Pala, L.1    Ciani, S.2    Dicembrini, I.3    Bardini, G.4    Cresci, B.5    Pezzatini, A.6
  • 39
    • 77649228014 scopus 로고    scopus 로고
    • Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes
    • Lee S, Yabe D, Nohtomi K, Takada M, Morita R, Seino Y, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 2010;57:119-26.
    • (2010) Endocr J , vol.57 , pp. 119-126
    • Lee, S.1    Yabe, D.2    Nohtomi, K.3    Takada, M.4    Morita, R.5    Seino, Y.6
  • 40
    • 84860252744 scopus 로고    scopus 로고
    • The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients
    • Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. Diabetes Obes Metab 2012;14:518-22.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 518-522
    • Fadini, G.P.1    Albiero, M.2    Menegazzo, L.3    De Kreutzenberg, S.V.4    Avogaro, A.5
  • 41
    • 31044456099 scopus 로고    scopus 로고
    • Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage
    • Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005;115:3554-63.
    • (2005) J Clin Invest , vol.115 , pp. 3554-3563
    • Knauf, C.1    Cani, P.D.2    Perrin, C.3    Iglesias, M.A.4    Maury, J.F.5    Bernard, E.6
  • 43
    • 79960710589 scopus 로고    scopus 로고
    • Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice
    • Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011;152:3018-29.
    • (2011) Endocrinology , vol.152 , pp. 3018-3029
    • Waget, A.1    Cabou, C.2    Masseboeuf, M.3    Cattan, P.4    Armanet, M.5    Karaca, M.6
  • 44
    • 79960729672 scopus 로고    scopus 로고
    • What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract
    • D'Alessio DA. What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract. Endocrinology 2011;152:2925-6.
    • (2011) Endocrinology , vol.152 , pp. 2925-2926
    • D'Alessio, D.A.1
  • 45
    • 84864803643 scopus 로고    scopus 로고
    • Mechanism of action of DPP-4 inhibitors: New insights
    • Vella A. Mechanism of action of DPP-4 inhibitors: New insights. J Clin Endocrinol Metab 2012;97:2626-8.
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 2626-2628
    • Vella, A.1
  • 46
    • 84856088215 scopus 로고    scopus 로고
    • Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue
    • Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, Brubaker PL. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology 2012;153:564-73.
    • (2012) Endocrinology , vol.153 , pp. 564-573
    • Sangle, G.V.1    Lauffer, L.M.2    Grieco, A.3    Trivedi, S.4    Iakoubov, R.5    Brubaker, P.L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.